Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.

TPS254Background: Inhibition of poly(ADP-ribose) polymerase (PARP) shows promise in prostate cancer, but is limited to the ~20% of men with defects in genes encoding for DNA repair proteins BRCA1, ...